Aldosterone-receptor antagonists in heart failure: Insights after EMPHASIS-HF

Current Heart Failure Reports

Volumn 8, Issue 1, 2011, Pages 7-13

  Jacob, Miriam S ^a   Tang, W H Wilson ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Aldosterone antagonist; Eplerenone; Heart failure; Hyperkalemia; Spironolactone

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EPLERENONE; MITOGEN ACTIVATED PROTEIN KINASE; NATRIURETIC FACTOR; PLACEBO; POTASSIUM; REACTIVE OXYGEN METABOLITE; SPIRONOLACTONE;

ARTICLE; CLINICAL PRACTICE; DISEASE ASSOCIATION; DRUG WITHDRAWAL; GLOMERULUS FILTRATION RATE; HEART ARREST; HEART FUNCTION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART VENTRICLE REMODELING; HOSPITALIZATION; HUMAN; HYPERKALEMIA; KIDNEY FUNCTION; MORBIDITY; MORTALITY; POTASSIUM BLOOD LEVEL; QUALITY OF LIFE; RISK BENEFIT ANALYSIS; SUDDEN DEATH; SYSTOLIC HEART FAILURE; TREATMENT OUTCOME;

ALDOSTERONE ANTAGONISTS; HEART FAILURE, SYSTOLIC; HUMANS; PATIENT SELECTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ALDOSTERONE; RESEARCH DESIGN; SEVERITY OF ILLNESS INDEX; SPIRONOLACTONE; TREATMENT OUTCOME; VENTRICULAR REMODELING;

EID: 79551552029     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0046-0     Document Type: Article

References (22)

1. D Lloyd-Jones RJ Adams TM Brown, et al. 2010 Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation 121 e46 e215 10.1161/CIRCULATIONAHA.109.192667 20019324
2. WH Tang RH Vagelos YG Yee, et al. 2002 Neurohormonal and clinical responses to high- versus low-dose enalapril therapy in chronic heart failure J Am Coll Cardiol 39 70 78 1:CAS:528:DC%2BD38Xnsl2mug%3D%3D 10.1016/S0735-1097(01) 01714-4 11755289 (Pubitemid 34059863)
3. Heart Failure Society of America 2010 Executive summary: HFSA 2010 Comprehensive heart failure practice guideline Journal of Cardiac Failure 16 475 539 10.1016/j.cardfail.2010.04.005 This article presents quideline recommendations from the HFSA, including current recommended use of aldosterone blockade
4. SA Hunt WT Abraham MH Chin, et al. 2009 2009 Focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the International Society for Heart and Lung Transplantation J Am Coll Cardiol 53 e1 e90 10.1016/j.jacc.2008.11.013 19358937 This article presents guideline recommendations from the ACC and the AHA, including indications for use of aldosterone blocakde
5. B Pitt F Zannad WJ Remme, et al. 1999 The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators N Engl J Med 341 709 717 1:CAS:528:DyaK1MXmtVyrurk%3D 10.1056/NEJM199909023411001 10471456 (Pubitemid 29407370)
6. B Pitt W Remme F Zannad, et al. 2003 Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction N Engl J Med 348 1309 1321 1:CAS:528:DC%2BD3sXis1ehurY%3D 10.1056/NEJMoa030207 12668699 (Pubitemid 36384098)
7. •• Zannad F, McMurray JJ, Krum H, et al.: Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms. N Engl J Med 2010. This article presents the EMPHASIS-HF study, the latest randomized control trial for the use of aldosterone antagonists in NYHA class II patients with systolic heart failure.
8. SD Solomon N Anavekar H Skali, et al. 2005 Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients Circulation 112 3738 3744 10.1161/CIRCULATIONAHA.105.561423 16330684 (Pubitemid 43739514)
9. DG Kramer TA Trikalinos DM Kent, et al. 2010 Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: a meta-analytic approach J Am Coll Cardiol 56 392 406 10.1016/j.jacc.2010.05.011 20650361 This article highlights the effect of aldosterone antagonists on markers of left ventricular remodeling
10. JA Ezekowitz FA McAlister 2009 Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials Eur Heart J 30 469 477 1:CAS:528:DC%2BD1MXit1ahtLY%3D 10.1093/eurheartj/ehn543 19066207
11. JE Udelson AM Feldman B Greenberg, et al. 2010 Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-to-moderate heart failure and left ventricular systolic dysfunction Circ Heart Fail 3 347 353 1:CAS:528:DC%2BC3cXot1eiurY%3D 10.1161/CIRCHEARTFAILURE. 109.906909 20299607
12. A Boccanelli GF Mureddu G Cacciatore, et al. 2009 Anti-remodelling effect of canrenone in patients with mild chronic heart failure (AREA IN-CHF study): final results Eur J Heart Fail 11 68 76 1:CAS:528:DC%2BD1MXjslSjtLo%3D 10.1093/eurjhf/hfn015 19147459
13. E Vizzardi A D'Aloia R Giubbini, et al. 2010 Effect of spironolactone on left ventricular ejection fraction and volumes in patients with class I or II heart failure Am J Cardiol 106 1292 1296 1:CAS:528:DC%2BC3cXhtlKjur%2FE 10.1016/j.amjcard.2010.06.052 21029826
14. H Izawa T Murohara K Nagata, et al. 2005 Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study Circulation 112 2940 2945 1:CAS:528:DC%2BD2MXhtFKqtrvI 16275882
15. F Zannad F Alla B Dousset, et al. 2000 Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators Circulation 102 2700 2706 1:STN:280:DC%2BD3M%2FmtVyntQ%3D%3D 11094035
16. Aldosterone Antagonist Therapy for Adults With Heart Failure and Preserved Systolic Function (TOPCAT). 2010. (Accessed December 6, 2010, at http://clinicaltrials.gov/ct2/show/NCT00094302?term=topcat&rank=1.)
17. H Kiyomoto K Rafiq M Mostofa A Nishiyama 2008 Possible underlying mechanisms responsible for aldosterone and mineralocorticoid receptor-dependent renal injury J Pharmacol Sci 108 399 405 1:CAS:528:DC%2BD1MXhvFWltQ%3D%3D 10.1254/jphs.08R02CR 19057124
18. DN Juurlink MM Mamdani DS Lee, et al. 2004 Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study N Engl J Med 351 543 551 1:CAS:528:DC%2BD2cXmtF2rtb0%3D 10.1056/NEJMoa040135 15295047 (Pubitemid 39025171)
19. DN Juurlink M Mamdani A Kopp, et al. 2003 Drug-drug interactions among elderly patients hospitalized for drug toxicity JAMA 289 1652 1658 1:CAS:528:DC%2BD3sXisF2isro%3D 10.1001/jama.289.13.1652 12672733 (Pubitemid 37430270)
20. M Svensson F Gustafsson S Galatius, et al. 2004 How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail 10 297 303 1:CAS:528:DC%2BD2cXmslOgtrk%3D 10.1016/j.cardfail.2003.10.012 15309695 (Pubitemid 39092680)
21. JW Funder 2008 Reconsidering the roles of the mineralocorticoid receptor Hypertension 53 286 290 10.1161/HYPERTENSIONAHA.108.119966
22. NM Albert GC Fonarow CW Yancy, et al. 2010 Influence of dedicated heart failure clinics on delivery of recommended therapies in outpatient cardiology practices: findings from the Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting (IMPROVE HF) Am Heart J 159 238 244 10.1016/j.ahj.2009.11.022 20152222 This is a study of the real-life utilization of guideline-recommended therapies (medical and device) in patients with systolic heart failure